Ivan Cohen-Tanugi
Founder at Minerva Lifesciences GmbH
Profile
Ivan Cohen-Tanugi is the founder of Minerva Lifesciences GmbH.
He previously served as the Chief Executive Officer of Eyevensys SAS.
Ivan also held the position of Chief Executive Officer & Director at Kuros Biosciences Ltd.
in 2017.
From 2019 to 2024, he worked as an Independent Director at Xbrane Biopharma AB.
Prior to that, Ivan was the Senior Vice President-International Operations at Stallergenes SA and Vice President at Amgen International AG.
Dr. Cohen-Tanugi obtained an MBA from École des Hautes Études Commerciales de Paris and a doctorate from the University of Grenoble.
Ivan Cohen-Tanugi active positions
| Companies | Position | Start |
|---|---|---|
| Minerva Lifesciences GmbH | Founder | - |
Former positions of Ivan Cohen-Tanugi
| Companies | Position | End |
|---|---|---|
| XBRANE BIOPHARMA AB | Director/Board Member | 2024-05-01 |
| KUROS BIOSCIENCES AG | Chief Executive Officer | 2017-12-03 |
| Amgen International AG | Corporate Officer/Principal | - |
| STALLERGENES | Chief Operating Officer | - |
Eyevensys SAS
 Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Chief Executive Officer | - |
Training of Ivan Cohen-Tanugi
| École des Hautes Études Commerciales de Paris | Masters Business Admin |
| University of Grenoble | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| XBRANE BIOPHARMA AB | Health Technology |
| KUROS BIOSCIENCES AG | Health Technology |
| Private companies | 4 |
|---|---|
Stallergenes SA
 Stallergenes SA Pharmaceuticals: MajorHealth Technology Stallergenes SA is an international biopharmaceutical company, which engages in the manufacture and sale of pharmaceutical products for the treatment of allergy-related respiratory diseases. The company operates through the Allergen Immunotherapy segment, which provides products and services for the desensitization of allergy-related respiratory conditions. Its products include a range of sublingual route and subcutaneous route products for the treatment of respiratory diseases such as rhino-conjunctivitis, rhinitis, and allergic asthma. Stallergenes was founded in 1962 and is headquartered in Antony, France. | Health Technology |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Commercial Services |
| Amgen International AG | |
| Minerva Lifesciences GmbH |
- Stock Market
- Insiders
- Ivan Cohen-Tanugi
